The role of glutamine metabolism in castration-resistant prostate cancer.

Bing Zhao; Jing Wang; Li Chen; Hong Wang; Chao-zhao Liang; Jiaoti Huang; Ling-fan XU

Return

The role of glutamine metabolism in castration-resistant prostate cancer.

Author: Bing ZHAO ¹ ; Jing WANG ² ; Li CHEN ¹ ; Hong WANG ³ ; Chao-Zhao LIANG ⁴ ; Jiaoti HUANG ⁵ ; Ling-Fan XU ⁴
Author Information

1. Department of Geriatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230002, China.
2. Department of Urologic Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.
3. Department of Nursing, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.
4. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.
5. Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
Publication Type:Review
Keywords: castration resistance; glutamine metabolism; prostate cancer; tumor metabolism
MeSH: Male; Humans; Glutamine/therapeutic use*; Prostatic Neoplasms, Castration-Resistant/drug therapy*
From: Asian Journal of Andrology 2023;25(2):192-197
CountryChina
Language:English
Abstract: Reprogramming of metabolism is a hallmark of tumors, which has been explored for therapeutic purposes. Prostate cancer (PCa), particularly advanced and therapy-resistant PCa, displays unique metabolic properties. Targeting metabolic vulnerabilities in PCa may benefit patients who have exhausted currently available treatment options and improve clinical outcomes. Among the many nutrients, glutamine has been shown to play a central role in the metabolic reprogramming of advanced PCa. In addition to amino acid metabolism, glutamine is also widely involved in the synthesis of other macromolecules and biomasses. Targeting glutamine metabolic network by maximally inhibiting glutamine utilization in tumor cells may significantly add to treatment options for many patients. This review summarizes the metabolic landscape of PCa, with a particular focus on recent studies of how glutamine metabolism alterations affect therapeutic resistance and disease progression of PCa, and suggests novel therapeutic strategies.